Ascentage Pharma Group International ADR Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.78 Intrinsic Value $24.14median of 2 methodsbased on filings through 31 Dec 2024 Market Price $16.31Price as of 30 Sep 2026 UndervaluedIntrinsic value is 48% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $1.5B Enterprise Value $1.5B All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Ascentage Pharma Group International is transitioning into a high-growth, commercial-stage biopharmaceutical leader driven by its dual-engine commercial assets: olverembatinib (the first approved third-generation BCR-ABL1 inhibitor in China) and lisaftoclax (the first approved China-developed Bcl-2 selective inhibitor). Following its dual-listing on Nasdaq in early 2025, the company has significantly de-risked its late-stage pipeline with nine ongoing global Phase III registrational trials. Strong commercial execution in China, combined with strategic global partnerships (such as with Takeda), positions the company for a major valuation inflection point as key Phase III readouts emerge in 2027. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$40.00 Mean target$47.56 High · most bullish analyst$55.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario Geopolitical tensions or regulatory hurdles delay global clinical trial enrollments or FDA filings. Commercial scaling of lisaftoclax in China faces intense competition, and R&D cash burn accelerates faster than product sales growth, requiring dilutive equity financing. Base CaseCentral scenario Olverembatinib maintains steady market penetration in China's CML segment, and lisaftoclax scales commercial sales in its first full years post-approval. Global Phase III trials (POLARIS-1, POLARIS-2, and GLORA-4) progress on track toward 2027 readouts, supported by a robust cash runway of over USD 350 million. Bull CaseUpside scenario Takeda exercises its option for olverembatinib's ex-China rights in 2027, triggering a massive milestone payment of over RMB 1 billion. Lisaftoclax successfully secures NRDL inclusion in China, accelerating market adoption, while global POLARIS trials read out positive data, paving the way for rapid FDA approvals. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |